多発性骨髄腫に対するVCAP療法

DOI Web Site PubMed 被引用文献2件

書誌事項

タイトル別名
  • VCAP Therapy for Multiple Myeloma
  • タハツセイ コツズイシュ ニ タイスル VCAP リョウホウ

この論文をさがす

抄録

Twenty-six patients with multiple myeloma, who had not recieved any previous chemotherapy, were treated with a VCAP regimen consisting of vincristine, cyclophosphamide, Adriamycin and prednisolone. This regimen was used not only for remission induction chemotherapy, but for maintenance therapy as well.<br>The response rate, evaluated by 50% or more reduction of M-protein, was 69% (18 of 26 patients). The median survival time was 44 months, which was longer than that reported by Alexanian. The patients in stage II survived longer than those in stage III, but the difference was not significant (p>0.05). The median survival times of the patients in stage IIIB and IIIA were 8.5 months and more than 49 months, respectively. Side effects, including leukopenia, gastrointestinal discomforts, peripheral neuropathy, and alopecia, were not serious.<br>These results suggest that the VCAP regimen is a useful combination chemotherapy for patients with multiple myeloma and that a maintenance therapy employing this regimen may prolong patients' survival time.

収録刊行物

  • 臨床血液

    臨床血液 28 (7), 1147-1151, 1987

    一般社団法人 日本血液学会

被引用文献 (2)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ